New study warning of dangers of gene editing in human embryos has relevance for agricultural GMOs
By Claire Robinson,
GMWatch
| 07. 03. 2023
Scientists have discovered that the cells of early human embryos are often unable to repair damage to their DNA caused by the CRISPR/Cas gene editing process. The researchers say that this has important implications for the proposed use of gene editing to repair mutated genes, which underlie serious inherited diseases, as well as for in vitro fertilisation (IVF) in general.
Commenting on her team's findings, lead researcher Dr Nada Kubikova from the University of Oxford, UK, said: “Gene editing has the potential to correct defective genes, a process that usually involves first breaking and then repairing the DNA strand. Our new findings provide a warning that commonly used gene editing technologies may have unwanted and potentially dangerous consequences if they are applied to human embryos.
“Our results show that the use of CRISPR/Cas9 in early human embryos carries significant risks. We have found that the DNA of embryo cells can be targeted with high efficiency, but unfortunately this rarely leads to the sort of changes needed to correct a defective gene. More often, the strand of DNA...
Related Articles
By Hannah Devlin, The Guardian | 05.14.2024
Photo by Kind and Curious from Unsplash
When Great Ormond Street hospital (Gosh) published the results of its gene therapy trial for “bubble baby” syndrome it was hailed as a medical breakthrough. The treatment had a more than 95% success...
By Victoria Bisset and Adela Suliman, The Washington Post | 05.09.2024
Photo by CDC from Unsplash
A baby girl born with profound genetic deafness can now hear unaided after receiving a “groundbreaking” gene therapy trial, Britain’s National Health Service said Thursday.
Opal Sandy, an 18-month-old from Oxfordshire, England, is the first...
By Carrie Arnold, Nature Biotechnology | 04.17.2024
Tome Biosciences came out of stealth mode on 12 December with a haul of over $200 million to develop the company’s gene editing platform. Tome’s first order of business was to snap up Replace Therapeutics to expand its toolkit to...
By Rob Stein, NPR | 04.24.2024
Lisa Pisano was lying in a hospital bed at NYU Langone Health, hooked up to beeping monitors and an array of tubes. Her surgical wounds were still healing, and she looked tired. But the 54-year-old New Jersey woman said she...